Troubled Valeant Pharmaceuticals International (TSX: VRX) has announced the departure of three executives, as the business continues to restructure at the close of a punishing 2016.
The Canadian company has already lost more than 80% of its market value since the year began, amid debt woes, the Philidor scandal, and a criminal investigation by the US Securities and Exchange Commission into its accounting and pricing practices.
"We continue working toward a recovery of our core prescription dermatology business"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze